search
Back to results

Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis (EOE)

Primary Purpose

Suspected Eosinophilic Esophagitis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Esophageal dilation
Steroid and Proton Pump Inhibitor Therapy
Sponsored by
Vanderbilt University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Suspected Eosinophilic Esophagitis focused on measuring eosinophilic esophagitis, esophageal food impaction, dysphagia

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female volunteers ≥18 years old.
  2. Patients with known or suspected Eosinophilic Esophagitis.
  3. Patients undergoing upper endoscopy for recent food impaction or complaint of dysphagia.

Exclusion Criteria:

  1. Use of oral corticosteroids.
  2. Significant medical conditions that in the investigator's judgment would compromise the subject's health and safety.
  3. Contraindication to esophageal dilation based on investigator's judgment.
  4. Esophageal motility abnormalities not thought to be related to Eosinophilic Esophagitis.

Sites / Locations

  • Vanderbilt Unversity Medical Center Department of Gastroenterology

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

A

B

Arm Description

Group A receives steroids and PPI, (SOC) and esophageal dilation.

Receives steroids and PPI only- Does not have esophageal dilation.

Outcomes

Primary Outcome Measures

Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE)
Dysphagia Scores: 0 = able to eat normal diet / no dysphagia. = able to swallow some solid foods = able to swallow only semi solid foods = able to swallow liquids only = unable to swallow anything / total dysphagia

Secondary Outcome Measures

Immunological Assessment Into the Etiology of Eosinophilic Esophagitis

Full Information

First Posted
August 25, 2008
Last Updated
October 4, 2017
Sponsor
Vanderbilt University
Collaborators
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT00880906
Brief Title
Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
Acronym
EOE
Official Title
Prospective, Single-Blinded, Randomized Controlled Trial With Sham Comparing Standard Therapy With or Without Esophageal Dilatation in Patients With Eosinophilic Esophagitis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
Collaborators
Takeda

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is for patients who have had a food impaction and/or difficulty swallowing, who are scheduled to have endoscopy, biopsy and possibly dilatation (stretching) of the esophagus. Standard treatment for people who have food impaction and difficulty swallowing is endoscopy to view the esophagus, tissue biopsies of the lining of the esophagus for diagnosis, and drug therapy including steroids and drugs used to treat reflux disease. Early dilatation or stretching of the esophagus may be done at this time but not always. Some doctors prefer to wait and see if the drugs are affective. It is not known if dilating the esophagus early in treatment adds benefit. Therefore, we are doing this study to compare the two methods of treatment. We will compare two groups: one group will have dilatation performed during the first endoscopy and one group will not have dilatation performed during endoscopy. We will see if dilatation helps prevent food impaction and improves swallowing. Another purpose of this study is to learn more about the causes of swallowing problems, thus extra biopsies will be taken of the esophagus and store them for future research.
Detailed Description
Eosinophilic esophagitis (EE) is an inflammatory condition of the esophagus found in the pediatric and adult population. It is characterized by an intense eosinophilic infiltration of the surface lining of the esophagus. EE is becoming an increasingly recognized diagnosis in individuals presenting with food bolus impaction and dysphagia. A history of chronic solid food dysphagia, food impaction and young age have all been noted characteristics in those patients subsequently diagnosed with EE. Eosinophilic esophagitis can be suspected by clinical presentation but histologic confirmation is necessary for a definitive diagnosis. The finding of large numbers of eosinophils (>15 per high powered field) on biopsy specimens are needed to confirm EE. Endoscopic features such as mucosal rings, linear furrows, proximal strictures and white esophageal papules have all been described in patients with EE. The underlying pathophysiology of EE is poorly understood but is thought to be associated with a TH2-type allergic inflammatory response. Other studies have also suggested that immune dysregulation may play a role in the underlying pathophysiology of this disorder. The optimal treatment of EE has not been determined. There have been studies noting that swallowed fluticasone propionate (FP), an inhaled corticosteroid, has shown benefit in adult and pediatric patients with EE. Esophageal dilation has been used in patients with EE with persistent dysphagia and food impaction. No study has evaluated the improvement in dysphagia and incidence of future food bolus impaction in those patients treated with early esophageal dilation. Our aim is to determine if esophageal dilation and standard drug therapy improves symptoms of dysphagia. We also plan to obtain and store esophageal biopsy specimens for future immunologic assessment to help determine the underlying pathophysiology Eosinophilic Esophagitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Suspected Eosinophilic Esophagitis
Keywords
eosinophilic esophagitis, esophageal food impaction, dysphagia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Active Comparator
Arm Description
Group A receives steroids and PPI, (SOC) and esophageal dilation.
Arm Title
B
Arm Type
Sham Comparator
Arm Description
Receives steroids and PPI only- Does not have esophageal dilation.
Intervention Type
Procedure
Intervention Name(s)
Esophageal dilation
Other Intervention Name(s)
esophageal stretching
Intervention Description
The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
Intervention Type
Drug
Intervention Name(s)
Steroid and Proton Pump Inhibitor Therapy
Other Intervention Name(s)
fluticasone, dexilant
Primary Outcome Measure Information:
Title
Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE)
Description
Dysphagia Scores: 0 = able to eat normal diet / no dysphagia. = able to swallow some solid foods = able to swallow only semi solid foods = able to swallow liquids only = unable to swallow anything / total dysphagia
Time Frame
60 days
Secondary Outcome Measure Information:
Title
Immunological Assessment Into the Etiology of Eosinophilic Esophagitis
Time Frame
60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female volunteers ≥18 years old. Patients with known or suspected Eosinophilic Esophagitis. Patients undergoing upper endoscopy for recent food impaction or complaint of dysphagia. Exclusion Criteria: Use of oral corticosteroids. Significant medical conditions that in the investigator's judgment would compromise the subject's health and safety. Contraindication to esophageal dilation based on investigator's judgment. Esophageal motility abnormalities not thought to be related to Eosinophilic Esophagitis.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael F Vaezi, MD,PhD, MS epi
Organizational Affiliation
vanderbilt Universtiy Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt Unversity Medical Center Department of Gastroenterology
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis

We'll reach out to this number within 24 hrs